owl liver publications
This article describes a parallel animal model / human NAFLD exploratory metabolomics study, using
ultra performance liquid chromatography-mass spectrometry (UPLC®-MS) to analyze 42 serum samples collected
from non-diabetic, morbidly obese, biopsy-proven NAFLD patients, and 17 animals belonging to the glycine Nmethyltransferase
knockout (GNMT-KO) NAFLD mouse model. Many of the altered metabolites observed could be
associated with biochemical perturbations associated with liver dysfunction (e.g. reduced Creatine) and inflammation
(e.g. eicosanoid signaling).
Journal of Proteome Research., Just Accepted
Publication Date (Web): July 15, 2010 (Article)
DOI: 10.1021/pr1002593
J. Caballería(1), J. Barr (2), A. Domínguez-Diez(3), A. Martin-Duce(4), O. Lo Iacono(5), Y. Le Marchand-Brustel(6), SC. Lu(7), and JM. Mato (8)
(1) Unidad de Hepatología, Hospital Clinic, Ciberehd. Barcelona. (2) OWL Genomics. Derio, (3) Hospital Universitario Marques de Valdecilla. Universidad de Cantabria. Santander, (4) Hospital de Alcalá de Henares Universidad de. Madrid, (5) Hospital del Tajo. Aranjuez, Madrid, (6) Institut National de la Sante et de la Recherche Medicale (INSERM). Nice, France. (7) Division of Gastrointestinal and Liver diseases, USC. Los Angeles, USA. (8) CIC bioGUNE, Unidad de Metabolomica. Ciberehd. Derio.
Gastroenterología y Hepatogía. Volumen 33, Especial Congreso AEEH. Febrero 2010.
With this web OWL Genomics intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a qualified
physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 09/06/2010
This site complies with the HONcode standard for trustworthy health information:
verify here.